The content on this site is intended for healthcare professionals only
Prof Garcia-Manero speaks with ecancertv at ASH 2016 about results from a phase II trial of pracinostat and azacitidine for elderly patients with acute myeloid leukaemia.
He describes how, while negative results for the combination in treating MDS might be attributed to inappropriate dose levels, pracinostat is proving highly efficacious in treating AML with a promising outlook on further combinations in randomised trials.
Prof Garcia-Manero also spoke with ecancer about the value of including patients who fail eligibility criteria in clinical trials.
ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Independent clones in CLL show oligoclonality and early evolution patterns
The need for improved healthcare infrastructure for extranodal NK/T-cell lymphoma in Latin America
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Advancements in paediatric Acute lymphoblastic leukemia management
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
ESMO 2024: Optimising the personalisation of prostate cancer treatment
